The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: Implications for association studies with human cancers
Corresponding Author
Elizabeth A. Waterman
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Fax: +44-114-2711711.
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United KingdomSearch for more papers by this authorNeil A. Cross
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorJenifer M. Lippitt
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorSimon S. Cross
Academic Unit of Pathology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorIshtiaq Rehman
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorIngunn Holen
Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorFreddie C. Hamdy
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorColby L. Eaton
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorCorresponding Author
Elizabeth A. Waterman
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Fax: +44-114-2711711.
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United KingdomSearch for more papers by this authorNeil A. Cross
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorJenifer M. Lippitt
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorSimon S. Cross
Academic Unit of Pathology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorIshtiaq Rehman
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorIngunn Holen
Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorFreddie C. Hamdy
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorColby L. Eaton
Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
Search for more papers by this authorAbstract
A commonly used monoclonal antibody targeting osteoprotegerin (OPG), MAB8051, detects a truncated protein species in breast and prostate cancer cell lysates. OPG expression has been reported to contribute to cell survival of both of these cancers. We hypothesised that the truncated protein represented a unique tumour-associated OPG isoform. However, here we show that the truncated protein identified by MAB8051 in cancer cell lines is carbonic anhydrase II (CA II), also implicated in tumour biology. We clearly demonstrate cross-reactivity of this OPG antibody in western blots. OPG and CA II RNA-interference studies confirmed the identity of the bands. We show almost identical staining patterns between MAB8051 and CA II immunohistochemistry of different human tissue types and human tumour types using serial sections. We conclude that care should be exercised using this antibody for immunohistochemistry studies, without additional in situ hybridisation, or parallel use of other OPG-specific antibodies. © 2007 Wiley-Liss, Inc.
References
- 1 Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309–19.
- 2 Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597–602.
- 3 Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363–7.
- 4 Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001; 57: 611–6.
- 5 Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006; 107: 289–98.
- 6 Perez-Martinez FC, Alonso V, Sarasa JL, Nam-Cha SG, Vela-Navarrete R, Manzarbeitia F, Calahorra FJ, Esbrit P. Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of pthrp and its pth1 receptor, osteoprotegerin and receptor activator of nuclear factor-kb ligand. J Clin Pathol 2007; 60: 290–4.
- 7 Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE, Holen I. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κβ ligand (RANKL) in human breast tumours. J Clin Pathol 2006; 59: 56–63.
- 8 Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MW, Holen I. Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. J Clin Pathol 2006; 59: 716–20.
- 9 Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002; 62: 1619–23.
- 10 Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003; 63: 912–6.
- 11 Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC, Eaton CL. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res 2004; 19: 1712–21.
- 12 Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, Holen I. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 2004; 86: 269–79.
- 13 Ito R, Nakayama H, Yoshida K, Kuraoka K, Motoshita J, Oda N, Oue N, Yasui W. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch 2003; 443: 146–51.
- 14 Mizutani Y, Matsubara H, Yamamoto K, Nan Li Y, Mikami K, Okihara K, Kawauchi A, Bonavida B, Miki T. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer 2004; 101: 1794–802.
- 15
Hofbauer LC,
Neubauer A,
Heufelder AE.
Receptor activator of nuclear factor-κβ ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.
Cancer
2001;
92:
460–70.
10.1002/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D CAS PubMed Web of Science® Google Scholar
- 16 Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 2005; 65: 1710–8.
- 17 Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001; 61: 4432–6.
- 18 Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, Findlay DM. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000; 15: 640–9.
- 19 Huang L, Xu J, Wood DJ, Zheng MH. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-κβ in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000; 156: 761–7.
- 20 Morinaga T, Nakagawa N, Yasuda H, Tsuda E, Higashio K. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. Eur J Biochem 1998; 254: 685–91.
- 21 Rehman I, Azzouzi AR, Catto JW, Allen S, Cross SS, Feeley K, Meuth M, Hamdy FC. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 2004; 64: 1238–43.
- 22 Himpel S, Panzer P, Eirmbter K, Czajkowska H, Sayed M, Packman LC, Blundell T, Kentrup H, Grotzinger J, Joost HG, Becker W. Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. Biochem J 2001; 359: 497– 505.
- 23 Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) 2006; 110: 279–91.
- 24 Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MW, Coleman RE, Holen I. Osteoprotegerin (OPG)—a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 2006; 118: 1901–8.
- 25 Onji M. In what types of diseases does anti-carbonic anhydrase II antibody-positivity have clinical significance? J Gastroenterol 1999; 34: 431–2.
- 26 Parkkila AK, Herva R, Parkkila S, Rajaniemi H. Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumours. Histochem J 1995; 27: 974–82.
- 27 Leppilampi M, Koistinen P, Savolainen ER, Hannuksela J, Parkkila AK, Niemela O, Pastorekova S, Pastorek J, Waheed A, Sly WS, Parkkila S, Rajaniemi H. The expression of carbonic anhydrase II in hematological malignancies. Clin Cancer Res 2002; 8: 2240–5.
- 28 Yoshiura K, Nakaoka T, Nishishita T, Sato K, Yamamoto A, Shimada S, Saida T, Kawakami Y, Takahashi TA, Fukuda H, Imajoh-Ohmi S, Oyaizu N, et al. Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. Clin Cancer Res 2005; 11: 8201–7.
- 29 Bianchi L, Canton C, Bini L, Orlandi R, Menard S, Armini A, Cattaneo M, Pallini V, Bernardi LR, Biunno I. Protein profile changes in the human breast cancer cell line MCF-7 in response to SEL1L gene induction. Proteomics 2005; 5: 2433–42.
- 30 Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents? Eur J Med Chem 2000; 35: 867–74.
- 31 Mallory JC, Crudden G, Oliva A, Saunders C, Stromberg A, Craven RJ. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol Pharmacol 2005; 68: 1747–56.
- 32 Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, Preissner KT, Hofbauer LC. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-κB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004; 89: 4104–12.
- 33 Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005; 204: 714–23.
- 34 Haynes DR, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, Zannetino A, Ahern MJ, Coleman M, Roberts-Thomson PJ, Kraan M, Tak PP, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) 2003; 42: 123–34.
- 35 Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, Makimura M, Ito K, Maeno M. Receptor activator of NF-κβ ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Life Sci 2007; 80: 1311–8.
- 36 Liu B, Sun D, Xia W, Hung MC, Yu D. Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1). J Natl Cancer Inst 1997; 89: 1524–9.
- 37 Rao VV, Anthony DC, Piwnica-Worms D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 1994; 54: 1536–41.
- 38 Hennard C, Pfuhl T, Buettner M, Becker KF, Knofel T, Middeldorp J, Kremmer E, Niedobitek G, Grasser F. The antibody 2B4 directed against the Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV association of human cancers. J Pathol 2006; 209: 430–5.
Citing Literature
